The flow and availability of essential medicines in the country remains in question. Patients with mental disorders and cancer, as well as those suffering from rare or orphan diseases, all experience this problem on a daily basis. Meanwhile, the struggle for answers from Invima by patient organizations and pharmaceutical companies continues.
According to Invima, 10.416 procedures have been handled so far this year. But for organizations such as the Colombian Federation of Rare Diseases (Fecoer), these figures are, at the very least, “not very transparent” and cause concern.
After reviewing the current, expired, cancelled, denied and renewal-processing health records of Invima, it was found that, as of July of this year, there are 2.685 active ingredients in the process of renewal...
Para leer completa esta noticia y otras de interés ingresa a la última edición de nuestra revista digital Gaffel News.
Sources:
Ver: Denuncian demoras de 4 años en registro sanitario de fármacos de dolencias huérfanas